Regorafenib improves progression-free survival and disease-control rate in patients with advanced GIST after failure to prior therapy with at least imatinib and sunitinib

Oral multikinase inhibitor regorafenib demonstrated substantial activity in a previous phase II trial in patients with gastrointestinal stromal tumor (GIST) after failure of both imatinib and sunitinib. The GRID phase III, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of regorafenib in this population with unmet clinical need. The results show improvement in progression-free survival and disease-control rate with regorafenib, and were presented by Dr George Demetri of the Dana-Farber Cancer Institute, Boston, during the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), 1-5 June, Chicago, USA. Read more here.